Clinical Trials · NCT00471237

A Phase II Study Evaluating SB-751689 in Post-Menopausal Women With Osteoporosis.

TerminatedPhase 2Teriparatide (Prohibited)
Phase
Phase 2
Recruitment status
Terminated
Sponsor
GlaxoSmithKline
Enrollment
564
Start date
May 2007
Locations
49 sites, 14 countries
Primary endpoint
Percent Change From Baseline in Bone Marrow Density (BMD) at Month 12 Measured by Dual-Energy X-Ray Absorptiometry (DXA) Scans of the Lumbar Spine (L1-L4)
View Teriparatide compound reference